Research Article

Interleukin 28B Gene Polymorphism and Association with Chronic Hepatitis C Therapy Results in Latvia

Table 1

Baseline characteristics of the patient’s profile.

CCNON-CCTOTAL

Average age, years353737 (18–68)
No. of patients, >40years15 (33%)40 (42%)54 (39%)
Male sex27 (59%)57 (59%)84 (59%)
BMI, kg/m225.226.225.9
BMI, >30 kg/m25 (11%)12 (13%)17 (12%)
Genotype 121 (46%)66 (69%)87 (61%)
Genotype 2, 325 (54%)30 (31%)55 (39%)
HCV-RNA, ×106 IU/mL (Genotype1)2.782.192.33
HCV-RNA, >600,000 IU/mL (Genotype 1)18 (39%)47 (49%)65 (46%)
ALT, U/L112 (17–325)104 (22–447)106 (17–447)
ALT, >ULN43 (93%)85 (88%)128 (90%)
GGT, U/L46.8 (9–228)88 (6–526)75 (6–526)
GGT, >ULN11 (24%)40 (42%)51 (36%)
Cholesterol, mM/L4.14 (2.09–7.35)4.6 (2.46–8.17)4.48 (2.09–8.17)
Triglycerides, mM/L1.17 (0.28–4.06)1.17 (0.3–5.44)1.11 (0.28–5.44)
Liver fibrosis* (Knodell)
F0
F1
F3
F4
0.975 (0–3)
9 (21.9%)
28 (68.3%)
4 (9.7%)
0
1.2 (0–4)
21 (24.7%)
47 (55.3%)
12 (14%)
5 (5.9%)
1.13 (0–4)
30 (23.8%)
75 (59.5%)
16 (12.7%)
5 (3.9%)
HAI index* (Knodell)6.44 (1–12)6.54 (2–13)6.5 (1–13)
Steatosis* > grade 034 (83%)65 (76.5%)99 (78.6%)
SVR34 (74%)50 (52%)84 (59%)

*Missing data: histology (non-CC), (CC).